Genmab A/SGMABNASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank93
3Y CAGR+4.7%
5Y CAGR+6.5%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+4.7%/yr
vs +44.2%/yr prior
5Y CAGR
+6.5%/yr
Consistent
Acceleration
-39.5pp
Decelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$8.43B-13.1%
2024$9.70B+63.1%
2023$5.95B-19.0%
2022$7.35B+75.7%
2021$4.18B-32.1%
2020$6.16B+105.0%
2019$3.00B+76.8%
2018$1.70B+14.2%
2017$1.49B+27.0%
2016$1.17B-